Therapeutic | Drozitumab |
Target | TNFRSF10B |
Heavy Chain | EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS |
Light Chain | SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL |
100% seqID Fv Structure | 4od2 [Fvs: BA] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4od2 [Fvs: BA] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2010 |
INN Year Recommended | 2011 |
Companies Involved | Genentech |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Chondrosarcoma, Colorectal cancer, Non-Hodgkin's lymphoma, Non-small cell lung cancer |
Notes |